XML Financial LLC Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

XML Financial LLC reduced its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 66.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. XML Financial LLC's holdings in Catalyst Pharmaceuticals were worth $242,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 91.5% during the 4th quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock valued at $1,241,000 after buying an additional 28,407 shares during the last quarter. Natixis Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 29.8% during the 4th quarter. Natixis Advisors LLC now owns 59,253 shares of the biopharmaceutical company's stock valued at $1,237,000 after buying an additional 13,616 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in Catalyst Pharmaceuticals by 18.7% during the 4th quarter. Teacher Retirement System of Texas now owns 31,655 shares of the biopharmaceutical company's stock valued at $661,000 after buying an additional 4,996 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Catalyst Pharmaceuticals by 7.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 21,419 shares of the biopharmaceutical company's stock valued at $447,000 after buying an additional 1,402 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Down 0.5%

Shares of CPRX stock traded down $0.11 during mid-day trading on Friday, hitting $21.78. 2,414,054 shares of the company's stock were exchanged, compared to its average volume of 1,110,491. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.97 and a fifty-two week high of $26.58. The stock has a 50-day simple moving average of $23.87 and a two-hundred day simple moving average of $22.90. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 0.89 and a beta of 0.72.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the transaction, the insider now owns 41,081 shares in the company, valued at $1,085,360.02. The trade was a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 247,924 shares of company stock worth $5,879,369. 10.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CPRX shares. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.